Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(02): 140-142
DOI: 10.4103/0971-5851.138960
COMMENTS AND CONTROVERSIES

Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014

Gilberto de Lima Lopes Junior
Department of Oncology, Centro Paulista De OncologiaE Hcor Onco, Brazil; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
19 July 2021

© 2014. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Lopes Gde L Jr, de Souza JA, Barrios C. Access to cancer medications in low- and middle-income countries. Nat Rev Clin Oncol 2013;10:314-22.
  • 2 Ku G, Tan IB, Yau T, Boku N, Laohavinij S, Cheng AL, et al. Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol 2012;13:e470-81.
  • 3 Tournigand C, Chibaudel B, Samson B, et al. Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial. J Clin Oncol 2013;31 Suppl; Abstr 3515.
  • 4 Parker JL, Lushina N, Bal PS, Petrella T, Dent R, Lopes G. Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Res Treat 2012;136:179-85.
  • 5 Falconi A, Lopes G, Parker JL. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer. J Thorac Oncol 2014;9:163-9.
  • 6 Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
  • 7 Peeters M, Oliner KS, Price TJ. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32: Suppl 3: Abstr LBA387.
  • 8 Ciardiello F, Lenz HJ, Kohne CH, et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 32:5s, 2014 (suppl; Abstr 3506.
  • 9 Tejpar S, Lenz HJ, Köhne CH, et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. J Clin Oncol 2014;32 Suppl 3: Abstr LBA444.
  • 10 Stintzing S, Jung A, Rossius L, et al. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3 - A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014;32 Suppl 3: Abstr 445.
  • 11 Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol 2014.
  • 12 Venook A, Niedzwiecki D, Lenz HJ. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:5s, 2014 Suppl; Abstr LBA3.
  • 13 Ku GY, Haaland BA, de Lima Lopes G Jr. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: The choice and schedule of fluoropyrimidine matters. Cancer Chemother Pharmacol 2012;70:231-8.
  • 14 Primrose J, Falk S, Finch-Jones M, Valle J, O′Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol 2014;15:601-11.